StreetInsider.com News Articles

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:

Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current